
|Videos|December 18, 2020
Safety, efficacy of KPI-121 0.25% for DED treatment
Author(s)David Hutton, Alex Delaney-Gesing
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Advertisement
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Retina experts reflect on how OCT transformed patient care
2
Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression
3
AAO 2025: 12-month outcomes of travoprost intracameral implant (iDose TR) in conjunction with cataract surgery
4
AAO 2025: The ASPIRE phase 2B trial of UBX1325 head-to-head against aflibercept
5



















































.png)


